Summary
Exceptionally Large and
Innovative Pipeline The breast cancer
pipeline is the largest in the pharmaceutical industry with 815 products in
active development across all stages. The range of mechanisms of action
employed by these compounds is also highly diverse, especially in comparison to
the existing market landscape.
More pertinently, the
degree and proportion of breakthrough innovations in this pipeline is
exceptional; GBI Research analysis identified 253 first-in-class programs in
the breast cancer pipeline, acting on 176 first-in-class molecular targets.
This accounts for some 39% of all products with a disclosed molecular target
and is reflective of the high degree of innovation in this indication. This has
far-reaching strategic implications for all market participants, as, despite
the high attrition rate in breast cancer, it is highly likely many of the
first-in-class technologies will reach the market over the coming decade and
may transform the clinical and commercial landscape.
Click for report details:
http://www.radiantinsights.com/research/frontier-pharma-breast-cancer-identifying-and-commercializing-first-in-class-innovation
Alignment of
First-in-Class Molecular Target with Disease Causation One of the key trends in oncology and in
breast cancer in particular over the last decade is the clinical and commercial
impact of targeted therapies designed to target proteins in signaling pathways
that are frequently mutated in a significant proportion of the patient
population. By aligning the molecular targets for therapeutic intervention with
disease causation and/or propagation, these therapies limit the systemic
cytotoxic effects whilst inhibiting tumor-promoting signaling pathways. Such
strategies thereby typically achieve superior efficacy and safety
profiles.
Our proprietary analyses
demonstrate significant levels of differentiation as to how well the
first-in-class products and their respective molecular targets align to
underlying gene and protein level mutations and dysfunction. More advanced
analytics further substantiated these findings as strong levels of
differentiation in the scientific and clinical rationale for first-in-class
molecular targets emerged. Furthermore, clear frontrunners were identified by
integrating analyses to assess the accessibility of molecular targets for
therapeutic compounds, the size of the target patient population that would
benefit from therapeutic intervention, and the expected positioning of the
first-in-class products based on the molecular targets and mechanisms of action
of currently marketed products.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment